<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637087</url>
  </required_header>
  <id_info>
    <org_study_id>18SFRN34110082</org_study_id>
    <nct_id>NCT04637087</nct_id>
  </id_info>
  <brief_title>Precision Medicine in Ischemic Stroke and Atrial Fibrillation</brief_title>
  <acronym>PreMISe-AF</acronym>
  <official_title>Precision Medicine in Ischemic Stroke and Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to minimize morbidity due to Atrial Fibrillation (AF). The&#xD;
      specific objective is to develop and implement a rational and personalized approach to AF&#xD;
      risk estimation that can inform management decisions with ischemic stroke. The investigators&#xD;
      propose to develop a clinical AF risk estimation tool in the electronic health record and to&#xD;
      test the effectiveness of implementing a clinical AF risk estimation tool into care for use&#xD;
      by stroke neurologists during the care of acute ischemic stroke patients at Massachusetts&#xD;
      General Hospital. The investigators will evaluate cardiac monitoring utilization calibrated&#xD;
      to AF risk by stroke neurologists using a custom electronic health record (EHR) notification&#xD;
      module.&#xD;
&#xD;
      The investigators hypothesize that cardiac rhythm monitoring utilization will be positively&#xD;
      correlated with the predicted risk of AF.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of cardiac rhythm monitoring</measure>
    <time_frame>6-months</time_frame>
    <description>Incidence of any cardiac rhythm monitoring in the 6-month follow-up period following discharge for an acute ischemic stroke. Cardiac rhythm monitoring will be ascertained based on electronic health record documentation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with implantable loop recorder orders</measure>
    <time_frame>12-months</time_frame>
    <description>Proportion of patients with implantable loop recorder ordered at discharge, 6-months, and 12-months. Implantable loop recorder orders will be ascertained based on electronic health record documentation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ambulatory wearable cardiac rhythm monitoring orders</measure>
    <time_frame>12-months</time_frame>
    <description>Proportion of patients with wearable cardiac rhythm monitor ordered at discharge, 6-months, and 12-months. Wearable cardiac rhythm monitoring orders will be ascertained based on electronic health record documentation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with cardiac monitor ordered by neurologist</measure>
    <time_frame>1-month</time_frame>
    <description>Proportion of patients with cardiac monitor ordered by the neurologist at discharge. Cardiac monitor orders by the neurologist will be ascertained based on electronic health record documentation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a new atrial fibrillation diagnosis</measure>
    <time_frame>12-months</time_frame>
    <description>Proportion of patients with a new diagnosis of atrial fibrillation at 12-months following discharge for acute ischemic stroke based on electronic health record documentation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with recurrent stroke</measure>
    <time_frame>12-months</time_frame>
    <description>Proportion of patients with recurrent stroke occurring within 12-months of discharge for an initial acute ischemic stroke. Recurrent stroke will be ascertained based on electronic health record documentation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients deceased</measure>
    <time_frame>12-months</time_frame>
    <description>Proportion of patients who die within 12-months of discharge for acute ischemic stroke. Death will be ascertained based on electroni health record documentation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with transesophageal echocardiogram utilization</measure>
    <time_frame>3-months</time_frame>
    <description>Proportion of patients with transesophageal echocardiogram (TEE) within 3-months of discharge for acute ischemic stroke. Transesophageal echocardiogram utilization will be ascertained based on electronic health record documentation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with oral anticoagulation prescription</measure>
    <time_frame>12-months</time_frame>
    <description>Proportion of patients with a new prescription for oral anticoagulation within 12-months of discharge following acute ischemic stroke. Prescriptions for oral anticoagulation will be ascertained based on electronic health record documentation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Atrial Fibrillation Risk Estimation Tool</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For eligible patients presenting with an acute ischemic stroke, a clinical atrial fibrillation risk estimation tool will be displayed in the patient's electronic health record through a best practice alert (BPA). The alert will display for the stroke neurologist caring for the patient when they first open the patient's chart. The neurologist may accept the automatically generated atrial fibrillation risk score displayed in the BPA, may modify some of the inputs of the score based on the patient's personal medical history and re-calculate, or may choose to dismiss the BPA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Atrial fibrillation risk electronic health record alert</intervention_name>
    <description>Electronic health record best practice alert which displays patient's 5-year risk of developing atrial fibrillation</description>
    <arm_group_label>Atrial Fibrillation Risk Estimation Tool</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 years or older&#xD;
&#xD;
          -  Presenting with a primary diagnosis of ischemic stroke or transient ischemic attack&#xD;
             admitted to Massachusetts General Hospital inpatient stroke service&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not meeting above inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A Lubitz, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Anderson, MD, MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven A Lubitz, MD, MPH</last_name>
    <phone>617-643-7339</phone>
    <email>slubitz@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana T Lipsanopoulos</last_name>
    <phone>617-726-9618</phone>
    <email>atlipsanopoulos@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey M Ashburner, PhD, MPH</last_name>
      <phone>617-724-3828</phone>
      <email>jashburner@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Steven A Lubitz, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Anderson, MD, MMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven A Lubitz</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

